Literature DB >> 32694169

Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?

Eleni E Ladikou1, Helena Sivaloganathan1, Kate M Milne1, William E Arter2, Roshan Ramasamy3, Ramy Saad3, Simon M Stoneham1, Barbara Philips4, Alice C Eziefula1, Timothy Chevassut5.   

Abstract

BACKGROUND: COVID-19 infection is characterised, among other features, by a prothrombotic state with high rate of venous thromboembolism (VTE), D-dimer, and fibrinogen levels. Clinical observations have also highlighted that these patients have elevated von Willebrand factor (vWF) and factor VIIIc.
METHODS: 24 consecutive COVID-19 positive patients were selected from the intensive care unit (ICU) or the high acuity ward of Brighton and Sussex University Hospitals NHS Trust.
RESULTS: The rate of VTE was 25% and mortality rate was 16.7%. Fibrinogen and D-Dimers were elevated, 7.9 (1.6) g/L and 2.4 (2.02) ug/ml respectively. Factor VIIIc and von vWF antigen levels were both extremely elevated at 279 (148) u/dL and 350 (131) % respectively, which are comparable to levels seen in ICU patients with severe sepsis. vWF levels were significantly higher in patients that died (p=0.017) and showed a positive correlation with age. There was a statistically significant association between COVID-19 disease and non-O blood group (p=0.02); 80% (4/5) of COVID-19 patients with VTE were blood group A.
CONCLUSION: Very high levels of vWF and factor VIIIc are common in COVID-19 patients, comparable to levels in severely septic non-COVID ICU patients. This could contribute to the hypercoagulable state and increased VTE rate in COVID-19. Further studies are needed to evaluate the use of vWF for stratifying thrombotic risk in COVID-19 and to determine if elevated vWF is contributing to disease pathogenesis. © Royal College of Physicians 2020. All rights reserved.

Entities:  

Keywords:  COVID-19; blood group; factor VIIIc; venous thromboembolism; von Willebrand factor

Mesh:

Substances:

Year:  2020        PMID: 32694169      PMCID: PMC7539718          DOI: 10.7861/clinmed.2020-0346

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  25 in total

1.  Influenza-associated thrombotic microangiopathy with unbalanced von Willebrand factor and a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 levels in a heterozygous protein S-deficient boy.

Authors:  Nobuyuki Tsujii; Keiji Nogami; Hiroyuki Yoshizawa; Masaki Hayakawa; Ayami Isonishi; Masanori Matsumoto; Midori Shima
Journal:  Pediatr Int       Date:  2016-07-20       Impact factor: 1.524

2.  Association between pneumococcal pneumonia and venous thromboembolism in hospitalized patients: A nationwide population-based study.

Authors:  Yu-Guang Chen; Te-Yu Lin; Wen-Yen Huang; Cheng-Li Lin; Ming-Shen Dai; Chia-Hung Kao
Journal:  Respirology       Date:  2015-02-27       Impact factor: 6.424

3.  H1N1 influenza (swine flu)-associated thrombotic microangiopathy with a markedly high plasma ratio of von Willebrand factor to ADAMTS13.

Authors:  Rui Akiyama; Isao Komori; Ryugo Hiramoto; Ayami Isonishi; Masanori Matsumoto; Yoshihiro Fujimura
Journal:  Intern Med       Date:  2011-03-15       Impact factor: 1.271

4.  Thrombotic risk in COVID-19: a case series and case-control study.

Authors:  Simon M Stoneham; Kate M Milne; Elisabeth Nuttall; Georgina H Frew; Beattie Rh Sturrock; Helena Sivaloganathan; Eleni E Ladikou; Stephen Drage; Barbara Phillips; Timothy Jt Chevassut; Alice C Eziefula
Journal:  Clin Med (Lond)       Date:  2020-05-18       Impact factor: 2.659

5.  [Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019].

Authors:  T Zhang; L X Sun; R E Feng
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2020-06-12

6.  D-dimer is a significant prognostic factor in patients with suspected infection and sepsis.

Authors:  Joaquín R Rodelo; Gisela De la Rosa; Martha L Valencia; Sigifredo Ospina; Clara M Arango; Carlos I Gómez; Alex García; Edilberto Nuñez; Fabián A Jaimes
Journal:  Am J Emerg Med       Date:  2012-07-15       Impact factor: 2.469

7.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.

Authors:  Ning Tang; Dengju Li; Xiong Wang; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-03-13       Impact factor: 5.824

8.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.

Authors:  Julie Helms; Charles Tacquard; François Severac; Ian Leonard-Lorant; Mickaël Ohana; Xavier Delabranche; Hamid Merdji; Raphaël Clere-Jehl; Malika Schenck; Florence Fagot Gandet; Samira Fafi-Kremer; Vincent Castelain; Francis Schneider; Lélia Grunebaum; Eduardo Anglés-Cano; Laurent Sattler; Paul-Michel Mertes; Ferhat Meziani
Journal:  Intensive Care Med       Date:  2020-05-04       Impact factor: 17.440

9.  Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.

Authors:  Janice Wang; Negin Hajizadeh; Ernest E Moore; Robert C McIntyre; Peter K Moore; Livia A Veress; Michael B Yaffe; Hunter B Moore; Christopher D Barrett
Journal:  J Thromb Haemost       Date:  2020-05-11       Impact factor: 5.824

10.  Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Authors:  Gian Battista Danzi; Marco Loffi; Gianluca Galeazzi; Elisa Gherbesi
Journal:  Eur Heart J       Date:  2020-05-14       Impact factor: 29.983

View more
  33 in total

1.  Von Willebrand factor.

Authors:  Pervinder Bhogal; Melanie Jensen; Dan Hart; Levansri Makalanda; George B Collins; Oliver Spooner; Ounali Jaffer
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

2.  Exacerbation of livedoid vasculopathy after coronavirus disease 2019.

Authors:  Ryoko Kawabe; Kyoko Tonomura; Yorihisa Kotobuki; Ikuko Ueda-Hayakawa; Hiroyuki Murota; Manabu Fujimoto
Journal:  Eur J Dermatol       Date:  2022-01-01       Impact factor: 2.805

3.  Exacerbation of livedoid vasculopathy after coronavirus disease 2019.

Authors:  Ryoko Kawabe; Kyoko Tonomura; Yorihisa Kotobuki; Ikuko Ueda-Hayakawa; Hiroyuki Murota; Manabu Fujimoto
Journal:  Eur J Dermatol       Date:  2022-02-15       Impact factor: 2.805

Review 4.  COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.

Authors:  Jae C Chang
Journal:  Vasc Health Risk Manag       Date:  2021-06-01

5.  Between inflammation and thrombosis - endothelial cells in COVID-19.

Authors:  Anna Birnhuber; Elisabeth Fliesser; Gregor Gorkiewicz; Martin Zacharias; Benjamin Seeliger; Sascha David; Tobias Welte; Julius Schmidt; Horst Olschewski; Malgorzata Wygrecka; Grazyna Kwapiszewska
Journal:  Eur Respir J       Date:  2021-05-13       Impact factor: 16.671

Review 6.  Coronavirus Disease 2019-Associated Coagulopathy.

Authors:  Giuseppe Lippi; Fabian Sanchis-Gomar; Emmanuel J Favaloro; Carl J Lavie; Brandon M Henry
Journal:  Mayo Clin Proc       Date:  2020-10-31       Impact factor: 7.616

7.  Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysis.

Authors:  Arief Wibowo; Raymond Pranata; Michael Anthonius Lim; Mohammad Rizki Akbara; Januar Wibawa Martha
Journal:  Int J Infect Dis       Date:  2021-06-27       Impact factor: 12.074

Review 8.  Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients.

Authors:  Andrzej Lange; Janusz Lange; Emilia Jaskuła
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

9.  Plasma P-selectin is an early marker of thromboembolism in COVID-19.

Authors:  Bánk G Fenyves; Arnav Mehta; Kyle R Kays; Marcia B Goldberg; Nir Hacohen; Michael R Filbin
Journal:  medRxiv       Date:  2021-07-14

10.  Letter in response to: Coagulation markers are independent predictors of increased oxygen requirements and thrombosis in COVID-19.

Authors:  Pervinder Bhogal; Melanie Jensen; George Collins; Oliver Spooner; Levansri Makalanda; Dan Hart; Ounali Jaffer
Journal:  J Thromb Haemost       Date:  2020-12       Impact factor: 16.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.